New Op-Ed from Former U.S. Commerce Secretary Gary Locke: Innovation drives Minnesota’s economy. Congress should lend a hand.
Former U.S. Ambassador to China, U.S. Secretary of Commerce, and Governor of Washington Gary Locke recently authored an opinion piece in the Minnesota Star Tribune highlighting the importance of two bipartisan bills to Minnesota’s innovation ecosystem. According to Locke, the Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act and the Patent Eligibility Restoration
Inventor Spotlight: William Shockley, John Bardeen, and Walter Brattain
C4IP is recognizing William Shockley, John Bardeen, and Walter Brattain, whose invention of the transistor made modern electronics possible. Shockley, Bardeen, and Brattain met in the 1940s at Bell Laboratories when they were hand-picked to work on developing a transistor, a device for generating and amplifying electrical signals. The trio succeeded after just two years,
Inventor Spotlight: William Shockley, John Bardeen, and Walter Brattain Read More »
Fact Check: Debunking Myths About Patents in the Pharmaceutical Industry
Activists affiliated with the Initiative for Medicines, Access & Knowledge (I-MAK) and R Street Institute have propagated false narratives about how patents stifle competition in the drug industry and keep generic drugs from coming to market. These erroneous arguments include the ideas that drug developers ‘game’ the FDA’s Orange Book, that they file unnecessary patents
Fact Check: Debunking Myths About Patents in the Pharmaceutical Industry Read More »
C4IP Coalition Updates: October 2024
October was a productive month for C4IP! Here’s a roundup of all that we accomplished over the past month. October Highlights: Spotlighting New Insights on Patent Quality On September 30, the nonprofit, nonpartisan Sunwater Institute released a policy report, “Patent Quality in the United States: Findings and Suggestions for Policymakers.” The report reviewed the U.S.
C4IP Coalition Updates: October 2024 Read More »
This Month in IP: October 2024
Strong, consistent IP protections throughout U.S. history enabled the creation of innovative and useful technologies that we use regularly today. From heart health to household appliances, every aspect of our lives has benefited greatly from IP, as shown by these historical examples from the month of October: 1962: On October 9, Wilson Greatbatch received a
This Month in IP: October 2024 Read More »
New Op-Ed from C4IP Co-Chair Andrei Iancu: Bill Is Key To Protecting US Economy From Patent Piracy, 10/25/2024
C4IP Co-Chair and former USPTO Director Andrei Iancu recently published an opinion piece in Law360 highlighting the importance of passing the bipartisan RESTORE Patent Rights Act. This bill, introduced by Senators Chris Coons (D-DE) and Tom Cotton (R-AR) and Representatives Nathaniel Moran (R-TX) and Madeleine Dean (D-PA), would reinstate injunctions as the default remedy in
Blog: Fact Check: The RESTORE Patent Rights Act Would Bolster America’s Innovation Economy, 10/18/2024
The RESTORE Patent Rights Act, introduced in July by a bipartisan group of senators and representatives, would be a pivotal legislative milestone for promoting innovation, if enacted into law. This bill would reestablish injunctive relief as the default legal remedy for patent infringement, preventing patent infringers from using others’ IP and ultimately facing little more
Inventor Spotlight: Shuji Nakamura
C4IP is recognizing Shuji Nakamura, who enabled modern-day electronics with his invention of the blue LED. Nakamura was born in 1954 in Ehime, Japan, and was working as a scientist for Japanese company Nichia Chemical when he became intrigued by light-emitting diodes (LEDs), which at the time could only emit red or green light and
Inventor Spotlight: Shuji Nakamura Read More »
New Op-Ed from C4IP Co-Chairs Andrei Iancu and David Kappos: Proposed Drug Patent Reforms Would Do More Harm Than Good
C4IP Co-Chairs and former USPTO Directors Andrei Iancu and David Kappos recently published an opinion piece in RealClear Health highlighting the unintended consequences that would arise if the Medication Affordability and Patent Integrity Act (MAPIA) is passed by Congress and signed into law. Supporters of the bill argue that drug companies take advantage of a